

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
February 21, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

February 21, 2007  
Date of Report (Date of earliest event reported)

-----  
ANTIGENICS INC.  
(Exact name of registrant as specified in its charter)

-----  
DELAWARE                      000-29089                      06-1562417  
(State or other jurisdiction      (Commission                      (IRS Employer  
of incorporation)                  File Number)                      Identification No.)  
  
162 Fifth Avenue, Suite 900  
New York, NY                      10010  
(Address of principal executive offices)                  (Zip Code)  
  
212-994-8200  
(Registrant's telephone number, including area code)  
-----

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02                  Results of Operations and Financial Condition

On February 21, 2007, Antigenics Inc. announced its financial results for the quarter and year ended December 31, 2006. The

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

The following exhibit is furnished herewith:

99.1 Press Release dated February 21, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: February 21, 2007

By: /s/ Garo H. Armen

-----

Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. -----	Description of Exhibit -----
99.1	Press Release dated February 21, 2007